NanoBio to Present Preclinical Data on its Novel, Nanoemulsion-based Vaccine Adjuvant Platform at the Immunotherapeutics & Vaccine Summit

ANN ARBOR, Mich.--(BUSINESS WIRE)--Aug 17, 2009 - NanoBio Corp. announced today that it is giving an oral presentation at the 2009 Immunotherapeutics & Vaccine Summit, which will include preclinical data demonstrating that its intranasal nanoemulsion adjuvant technology significantly enhances the immune response to influenza vaccines. The presentation details are as follows:

        Oral Presentation:       W805EC, a Novel Nanoemulsion Adjuvant, Enhances the Immune Response to Commercial Influenza Vaccines Following Nasal Administration in Ferrets

 


 
        Date:       Wednesday, August 19 at 10:30 AM
        Location:       Renaissance Providence Hotel in Providence, Rhode Island

 


 


During the presentation, NanoBio will share data demonstrating that intranasal nanoemulsion-adjuvanted influenza vaccines:

 


  • Elicit strong immune responses after a single vaccination using as low as 1/50th of the antigen dose found in currently marketed vaccines;
     
  • Provide broad cross protection against a range of other influenza A strains not included in the vaccine administered; and,
     
  • Presented no safety or tolerance concerns in ferrets when administered nasally.
     

About NanoBio's Vaccine Platform

NanoBio's nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against seasonal and pandemic influenza, hepatitis B, RSV, HIV, pneumococcal, anthrax, smallpox and other diseases. The company's NanoStat™ adjuvant platform technology has demonstrated numerous potential advantages over traditional vaccines, including: the ability to generate robust mucosal, systemic and cellular immunity; antigen-sparing qualities; cross-protection against non-vaccinated strains; ability to adjuvant multiple antigen types without inducing inflammation; thermally stabilizing the vaccine; and removing the need for needles.

NanoBio Corp. announced earlier in 2009 that the U.S. Food and Drug Administration (FDA) approved the company's Investigational New Drug (IND) application for the Phase 1 clinical study of NB-1008 for a seasonal influenza vaccine administered via a nasal dropper. This Phase 1 study is ongoing.

About NanoBio

NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company's lead dermatology and anti-infective product candidates include treatments for herpes labialis (cold sores), onychomycosis (nail fungus), tinea capitis, acne, molluscum contagiosum, and cystic fibrosis. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.

Contact: NanoBio Corp.
John Coffey, 734-302-9107
Vice President, Business Development
john.coffey@nanobio.com
or
Media:
Schwartz Communications
Stacey Holifield, 781-684-0770
nanobio@schwartz-pr.com

Posted: August 2009

View comments

Hide
(web1)